Helogen raises $7.1M before two October orbital biomaterial missions
Shishir Bankapur plans to put Helogen's seed financing behind HEL-IOS hardware, two October flights and the manufacturing data needed to pursue medical uses on Earth.
By Ryan Merket · Published
Primary source: FinSMEs
Why it matters
Helogen says its internal-material and customer missions already generate revenue, but it has not disclosed the scale. The October flights are expected to test the complete HEL-IOS platform for the first time and show whether its manufacturing records can support eventual medical-product review.
Shishir Bankapur, founder and CEO of Helogen, has raised a $7.1 million seed round to move his orbital biology venture from remotely operated experiments toward manufacturing biomaterials intended for medical implants. FinSMEs reported that RRE Ventures and Oceans co-led the financing, with One Way Ventures and Blisce participating.
Bankapur's public profile lists chemical engineering studies at Drexel University and earlier roles including founder and CEO of artificial-intelligence company Clarke.ai. Public materials suggest Helogen is an evolution of Bankapur's earlier venture, Odyssey SpaceWorks, although the precise corporate relationship is not confirmed. Public materials describe Odyssey SpaceWorks as an earlier space-biology venture founded by Bankapur.
The original thesis was straightforward: researchers on Earth should be able to control biological experiments aboard small satellites without becoming spacecraft operators. Helogen has expanded that model into autonomous production. Helogen is developing orthopedic and regenerative-medicine materials internally while offering orbital production systems to outside biotechnology developers.
Helogen's company announcement describes operations in Los Angeles and lists New York as its headquarters. Helogen is pursuing customer-funded biological research, although it has not disclosed pricing, customer counts or production volumes.
A seed round with a flight deadline
Helogen plans two orbital missions in October 2026. Payload reports that the flights are expected to be the first missions for the complete HEL-IOS platform. Helogen has earlier space-biology activity, but the complete platform has not yet flown.
One mission will focus on Helogen's biomaterials for orthopedic applications. These remain development programs and are not approved medical products.
The other mission will support LambdaVision, according to Payload. LambdaVision is developing a protein-based artificial-retina material, and the flight will support its work to manufacture that material in orbit.
Those flights are the immediate use for the financing. Helogen needs to fabricate flight hardware, operate missions, collect manufacturing data and establish quality controls before it can make a credible case for dedicated orbital infrastructure.
Helogen says in its September announcement that financing to date supported two previous missions, development of its first spacecraft and HEL-IOS, NASA TechLeap recognition and commercial partnerships. The seed financing will support hardware fabrication, hiring and customer-funded biological research.
FinSMEs describes a $7.1 million seed round, while Helogen's September announcement reports $7.9 million raised to date. The reason for the difference is not disclosed. Helogen has not disclosed a valuation.
Building the whole orbital factory
HEL-IOS combines bioreactors, the Cellular Experiment Laboratory System, HEL-ICS controls, autonomous analysis and spacecraft hardware.
That integrated approach is Bankapur's central product decision. Helogen is building manufacturing machinery, control software and spacecraft as one system instead of fitting a biology payload into a vehicle designed for another purpose.
Helogen is pursuing two business lines: developing its own orthopedic and regenerative-medicine materials and operating orbital production systems for outside biotechnology developers. Bankapur told Payload that both categories already generate revenue through customer work, deposits and research and development fees. Helogen has not disclosed revenue, customer counts, pricing or production volumes, so the scale of that activity cannot be assessed.
Helogen's partnership with LambdaVision shows how the outside-customer model is supposed to work. LambdaVision is developing a protein-based artificial retina using microgravity processes. The implant remains under development and is not approved for clinical use.
In a February 18 announcement, Starlab Space announced a partnership with Helogen.
The hard part begins with process control
Microgravity manufacturing already has technical precedent. NASA is supporting Auxilium Biotechnologies' orbital printing of implantable devices designed to assist nerve regeneration.
Other commercial space-biotechnology companies divide the market differently. Varda Space Industries couples in-space processing with capsule return, while SpacePharma and Rhodium Scientific focus on remotely operated microgravity laboratories. BioOrbit is pursuing orbital crystallization and reformulation of biologic drugs. Those companies appear alongside Helogen in a directory of commercial space-biology ventures, although their products and target markets are not direct equivalents.
Helogen is trying to turn mission-based work into a standardized production service outside the International Space Station. Its performance will depend on flight frequency, material recovery and process consistency. An experiment can show that a biomaterial forms differently in microgravity. A medical product requires traceable handling, contamination controls, repeatable batches and evidence supporting regulatory review.
Helogen's September mission announcement says the October flights will collect data on sterility, material recovery, consistency and chain of custody. Bankapur told Payload that maintaining sterility, traceability and accountability will be central to the missions.
A NASA Space Act Agreement confirms that Helogen was selected for the agency's 2025 TechLeap program. The support concerns flight-technology development and does not constitute approval of Helogen's materials for medical use.
On its website, Helogen describes Keystar as a "lights-out factory base" with power, thermal management, autonomy, communications and docking for production systems. Helogen targets 2028 for operation, a schedule that will require substantially greater capital and repeated flight performance.
Putting an internal orthopedic-material program and an outside customer's artificial-retina material through HEL-IOS will test Helogen's central product claim: that one integrated platform can support distinct biological manufacturing processes while preserving the records required for regulated products. Failure on sterility, recovery or traceability would leave the company with another orbital experiment rather than a production service.